Remicade Most Cost-Effective Biologic For Psoriasis In ICER Analysis
Executive Summary
Analysis by the Institute for Clinical and Economic Review finds Remicade offers the 'greatest benefit per dollar spent' in treating psoriasis compared to other biologics, which are considered 'moderately” cost effective.
You may also be interested in...
Psoriasis Drug Valuation By ICER May Undercut Routine Step Therapy
Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices.
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.